August 28, 2024
aXichem: Starkt Q2 väcker förväntningar
We create value.
aXichem is an innovative biotechnology company specialising in development of natural analogue ingredients.
AXICHEM A
(AXIC A)
1.275
SEK
-0.07 / -4.85%
High
1.35
Low
1.23
Volume
45141
Turnover
57911.91
January 20, 2025 17:25:00
Financial Calendar
Year-end report 2024 - 27 February 2025
Q1 Report, Jan – March 2025 - 22 May 2025
Annual Report 2024 - 28 May 2025
Annual General Meeting - 18 June 2025
Q2 Report, Jan – June 2025 - 28 August 2025
Q3 Report, Jan – Sept 2025 - 28 November 2025
Year End Report 2025 - 26 February 2026
Company description
We draw from the genius of nature and respect nature in return.
aXichem Bolagsbeskrivning 131121
PDF 1.28 MB
Certified Advisor
Västra Hamnen Corporate Finance
Jungmansgatan 12
211 11 Malmö
General Meetings Archive
Investor Structure
aXichem’s ten largest owners according to the shareholders’ register kept by Euroclear as of 2024-06-28.
Total number of shares: 40 305 615.
| Name | No. of shares | Participating interest (%) |
| LMK-bolagen | 6 233 023 | 15,46 |
| Manakin Ltd | 2 913 484 | 7,23 |
| Avanza Pension | 2 151 655 | 5,34 |
| Nordnet Pensionsförsäkring AB | 1 792 656 | 4,45 |
| Aksjesel. Arbejdenes Landsbank | 1 176 736 | 2,92 |
| Myacom Investment AB | 1 133 400 | 2,81 |
| Fenja Capital II | 930 000 | 2,31 |
| Sydbank | 875 913 | 2,17 |
| Pierre Sahlstrand | 862 999 | 2,14 |
| Christian Månsson | 762 697 | 1,89 |
Investor enquiries
Subscribe to information from aXichem